RESULTS	Pain progression at week 13 occurred in 174 ( 28 % ) of 625 evaluable patients in the enzalutamide group versus 101 ( 39 % ) of 259 patients in the placebo group ( difference -112 % , 95 % CI -181 to -43 ; p = 00018 ) .\